DNA (93.50) is now trading about 5% above Roche’s cash offer. As noted, I think serious negotiations between Roche and DNA’s independent directors start at $100/sh.
Let’s talk biotech! “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Dew--do you think that there is any chance of stock deal in lieu of cash? All of the recent biotech buyouts that I can think of have all been for cash. As a shareholder of DNA I would not mind receiving Roche stock.
Market Data 
Markets 
AI
